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Abstract
As a short-lived radical that diffuses across membranes, rather than interacting with membrane-bound receptors,
nitric oxide (NO) represents a significant departure from synthetically derived radiosensitizers. An endogenous com-
pound, NO may equal or surpass its molecular cousin, oxygen, as a hypoxic radiosensitizer, through pleiotropic
phenotypic effects on tumor perfusion, cell signaling, mitochondrial respiration, the fixation of radiation-induced
damage, and the radioprotection of normal tissue. However, unlike oxygen, in the context of radiosensitization, the
clinical role and utility of NO are poorly understood,with often contradictory and controversial reported effects:whether
NO functions as a radiosensitizer may ultimately be contextual to the tumor microenvironment. This may make NO
manipulation an ideal candidate for a personalized radiosensitization approach tailored to specific patient and tumor
types/microenvironmental characteristics. Effective delivery of NO both systemically and directly to the tumor may
be critical to the success of this approach. Compounds that release NO or NO precursors have the potential to drive
innovation and result in a new fertile branch of the radiosensitizer tree.
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Introduction
Do I contradict myself ?
Very well then I contradict myself,
(I am large, I contain multitudes.)
Walt Whitman, Song of Myself
“NO” may be the most basic and primal word in the English
language but its semantic interpretation is influenced by a complex
interplay of contextual factors. The meaning of this seemingly simple
negative word is thus shaded with subtlety and ultimately depends on
factors such as inflection, tone, use of gesture, phrasing, and volume.
Similarly, in hypoxic radiosensitization, the actions of the deceptively
simple molecule, NO or nitric oxide, seem to be very much depen-
dent on the “biologic” context, consisting of diverse parameters such
as dose, oxygenation status, delivery method, vessel architecture,
site of administration, and the tumor microenvironment. The basic
molecular structure of NO belies the central importance of its subtle
and protean biology. As one of the oldest and most primitive mole-
cules, NO may have evolved from a critical defense mechanism [1]
against ozone toxicity to subserve more complex and diverse func-
tions. A vasodilator, neurotransmitter, antimicrobial, and immune
regulator, NO is a “master regulator” [2], consummate multitasker
and jack of all trades that possesses more than 36 different functions
[3] with activity in every major organ system. A master flip-flopper
as well, the molecule is nearly impossible to pin down.
NO is generated endogenously by NO synthase (NOS) in mammals
from the oxidation of L-arginine to L-citrulline (Figure 1). NO can also
be formed independent of NOS by the reduction of nitrate and nitrite
catalyzed by reductive enzymes such as deoxyhemoglobin and nitrate
reductase. NOS can be categorized into two functional classes: con-
stitutive (cNOS) and inducible (iNOS), based on their sensitivity to
calcium [4]. As a gaseous short-lived free radical that is uncharged
and therefore freely diffusible across tissues and cell membranes, NO
is able to bind to its most sensitive known target, soluble guanylate
cyclase, to stimulate the production of cyclic GMP, which is responsi-
ble for downstream NO-mediated signaling.
Unlike the specific and highly selective lock-and-key fit used by most
other types of signal transducers, NO can react both directly and indi-
rectly with multiple other partners. Indirectly, NO has the potential to
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generate multiple species with distinct biochemical properties, resulting
in variable and unpredictable biologic effects. In addition, NO is both
rapidly synthesized and metabolized, making it an ideal signaling
molecule for rapid, transient responses.
In the context of radiosensitization, given the complexity, promiscu-
ity, and pluripotency of this molecule [3], it is perhaps not surprising
that the literature is contradictory, with some studies demonstrating
measurable benefits of the combination of NO with radiotherapy,
whereas others demonstrate a deleterious effect. NO is a paradox, alter-
nately acting as a prooxidant and an antioxidant, a radiosensitizer and a
radioprotector, and a dual regulator of apoptosis, both inducing and
preventing apoptosis. This has led to an intense debate, in which both
sides can claim evidence of support, as to whether NO is good or bad,
friend or foe [5]. As a “foe,” increased levels of NOS have led to poorer
survival in cervical cancer patients after radiotherapy [5]. It also has
been reported that iNOS is expressed in several human cancers in-
cluding breast, pancreatic, head and neck, and gynecologic tumors
[6], which strongly implies that NO may be an important promoter
of tumor growth and metastasis [7]. Paradoxically, perhaps, tumor
shrinkage and decreased blood flow were associated with administration
of the NOS inhibitor, N -nitro-L-arginine (L-NNA) in a phase 1 study
of non–small cell lung carcinoma, as assessed by dynamic contrast-
enhanced computed tomography. These data would suggest that NO
donation could increase both tumor perfusion and tumor growth [8].
As a “friend,” NO has been widely reported as a hypoxic cell radio-
sensitizer [9], in its effects on systemic and hypoxic vasodilation, red
cell rheology, and decreased oxygen use. These are discussed more
fully below.
In reality, then, it might be more accurate to consider NO from
a multidimensional perspective, to explore the combined effects of
NO local concentration, the biologic milieu, and interactions with
oxygen on NO-mediated activity. At low concentrations, NO pro-
motes tumor cell survival and angiogenesis, whereas at higher levels,
when homeostatic balance is perturbed, NO can act as an antitumor
agent [10]. For example, NO can combine with superoxide anions
(O2
−) to form toxic peroxynitrite (ONOO−), triggering apoptosis
through direct and indirect mechanisms and contributing to radio-
sensitizing effects. This notion of a dose threshold and threshold
effects is central to NO induced cytotoxicity [11].
Therefore, the focus of the current article is on NO and its relation-
ship to oxygen and radiosensitization; relevant aspects ofNOphysiology
will be highlighted in an attempt to place its dual, seemingly contradic-
tory, function into a wider context and to explore the potential utility
of NO modulation as a promising, but currently unrealized, means of
improving radiation sensitivity.
The Oxygen Effect
From the early role of NO in the evolution of life [1], to its discovery
by the chemist Joseph Priestley, credited with isolating oxygen, the
history of NO is closely intertwined with oxygen. Oxygen is the pri-
mary determinant mover of radiosensitization: the biologic effect of
XRT is increased by a factor of 2 to 3 in the presence of oxygen, whereas
radioresistance is associated with hypoxia. According to “the oxygen
fixation hypothesis,” DNA is indirectly damaged by reactive oxygen
species from the radiolysis of water molecules. The permanence of this
damage is dependent on subsequent modification of DNA radicals.
Under aerobic conditions, oxygen reacts through its two unpaired elec-
trons with DNA radicals to form DNA peroxy radicals, thus prevent-
ing DNA repair. Under hypoxia, the DNA radical is quenched through
thiol-mediated hydrogen atom donation and DNA crosslinks can be
repaired (Table 1).
Therefore, one approach to increase radiosensitivity is to improve
the oxygen status of tumors [12]. Reoxygenation, however, is com-
promised by limited diffusion of oxygen inside tumors due to consump-
tion by actively respiring cells and the distance of peripheral blood
vessels to the center of the tumor. Highly electron-affinic compounds
such as the nitroimidazoles, behaving as oxygen mimics, penetrate
further than oxygen. However, although these molecules were demon-
strated to be effective radiosensitizers, the nitroimidazoles suffer from
dose-limiting neurotoxicities that preclude their clinical use [12].
Nitric Oxide
NO has an electron affinity comparable to oxygen. NO acts as a
hypoxic radiosensitizer in its own right, mimicking the effects of
oxygen on fixation of radiation-induced DNA damage [13]. However,
NO has an extremely short circulating half-life, lasting only milli-
seconds that is not compatible with its long duration of action and
far-reaching effects. Consequently, NO may exert cytotoxicity through
Figure 1. The nitrate-nitrite-NO pathway. NO is generated from the precursor L-Arginine by the enzyme NOS under normoxic conditions.
Under these conditions, NO is oxidized to nitrite and nitrate. Under hypoxia, nitrite is reduced by a variety of NOS-independent processes
to form NO.
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the bystander effect, mediated by diffusion into the tumor interstitium
and across tumor cell membranes [14]. Consequently, radio enhance-
ment may occur with only marginal fluxes in NO.
However, increased radiosensitivity cannot be attributed exclusively
to the NOmolecule itself, but is combined with the oxygen effect [15]:
The cytotoxic effects of NO derive both from the reaction of NO with
O2
− to form the peroxynitrite anion ONOO− and from modulation of
oxygen consumption and delivery.
In the anthropomorphic characterization of reactive nitrogen spe-
cies, NO has been viewed as good, superoxide as bad, and peroxide
as ugly [5]. The short half-life [16] of NO may be partly explained
by its rapid reaction with superoxide to form the peroxynitrite ion.
Peroxynitrite causes apoptotic or necrotic cell death through nitration
of tyrosine residues in proteins, lipid peroxidation, oxidation of critical
thiols [17], DNA strand breakage, and activation of the nuclear enzyme
poly(ADP-ribose) polymerase, leading to NAD+ depletion and energy
failure [18]. At physiologic pH, peroxide combines with NO to form
nitrogen dioxide and hydroxyl radicals [19], before oxidizing to nitrate,
most often considered inert, and nitrite, which can be cycled back to
NO and other reactive nitrogen oxide species [17] through hypoxia-
mediated reduction.
Increased NO-Mediated Tumor Oxygenation
Vasodilatation and the Steal Effect
The administration of NO donors to control tumor blood flow is
controversial. Some studies have reported improved tumor oxygenation
and radiosensitization through increased blood flow, whereas others are
consistent with the promotion of tumor growth and decreased tumor
perfusion [20].
These apparently contradictory results could be attributed to the
idiosyncrasies of the tumor microenvironment resulting in blood flow
redistribution through steal or anti–steal effects. Because tumor blood
vessels are fully dilated, a “steal effect” involves a relocation of blood
away from the tumor as a result of NO-mediated systemic vasodila-
tion. An anti–steal effect increases tumor blood flow and oxygenation
through preferential vessel relaxation or systemic vasoconstriction [21].
Results from a phase 2 clinical study suggest that NO mediates
vasodilation in tumors. Prostate cancer patients who had failed pri-
mary therapy were treated with low-dose, sustained delivery of glyceryl
trinitrate resulting in a significant decrease in PSA. The authors sug-
gested that, although low-dose NO had no direct cytotoxic effect, NO
decreased the emergence of a more malignant phenotype, including
invasion and metastases, presumably by decreasing tumor hypoxia
through improved tumor blood flow [10]. A possible alternative and
intriguing rationale for these observations is that the sustained delivery
of NO paradoxically resulted in inhibition of NO signaling through
tachyphylaxis [22]. The tachyphylaxis may have resulted from inhibition
of guanylate cyclase through a feedback mechanism [23]. In this case,
the results may have been due to a vasoconstrictive intratumoral effect
because the patency of tumor vessels is highly dependent on constitutive
NO production [24].
Red Cell Rheological Effects
Recent studies have demonstrated that renitration of stored blood with
exogenous NO donors can reverse the rheological effects (crenation) on
RBCs due to hypoxia and acidosis and thereby improve tissue perfusion
and oxygenation on transfusion [25]. By analogy, NO should restore
normal red cell shape and normalize blood viscosity in the relatively
hypoxic, malformed, and tortuous tumor microvessels, increasing over-
all flow through the tumor. These hemodynamic changes would be ex-
pected to result in a radiosensitizing effect by improved oxygen delivery
through relief of hypoxia.
Hypoxia and Hypoxic Vasodilation
The presence of hypoxia in the microenvironment would be expected
to influence the susceptibility of tumors to nitrovasodilation with the
two types of hypoxia, chronic and acute, responding differently. Long-
term or diffusion-limited hypoxia is related to the maximum distribu-
tion distance of oxygen in actively respiring tumor tissue, creating an
O2 tension gradient as the distance from vessels increases. Acute or
transient hypoxia involves a temporary restriction of blood flow to areas
of the tumor by transiently constricted or blocked vessels, resulting in
local ischemia.
The vasculature of acutely hypoxic tumors may be more susceptible
than chronically hypoxic tissues to the vasoactive and rheological prop-
erties of NO through relief or prevention of temporary flow stasis.
The hypoxia marker, pimonidazole, a 2-nitroimidazole, has been
used to estimate hypoxia and perfusion in tumors [26]. In some tumors,
a predominance of pimonidazole-positive areas in the vicinity of blood
vessels indicates transient perfusion and acute hypoxia.
NO reacts with a highly conserved reduced cysteine at position 93
on the β chain of hemoglobin to form an S -nitrosothiol (SNO). This
has implications for selective hypoxic vasodilation and, by extension,
radiosensitization through increased oxygenation. It has been proposed
that under normoxic conditions, NO binds to this cysteinyl residue
on deoxyhemoglobin to form S-nitrosohemoglobin (SNOHb). Under
hypoxic conditions, the allosteric transition in S -nitrosohemoglobin
from the R (oxygenated) to the T (deoxygenated) conformation trans-
fers NO to a cysteine in the membrane of the red cell. The red cell thus
serves as the NO gatekeeper, sequestering NO equivalents in normoxia
and dispensing them “altruistically” in hypoxia [27].
An alternative hypothesis posits that it is nitrite, rather than SNOHb,
which is responsible for preserving NO bioactivity in the circulation
[28]. In any event, whether the carrier is nitrite or SNOHb, NO
Table 1. Mechanisms of NO Radiosensitization Effects.
Treatment Systemic Effects Local Effects
NO donors (tumor-type dependent) Vasodilation and steal effect Increased oxygenation
Red blood cell rheology modification Release of NO by RBCs under hypoxic conditions
Local Oxygen sparing through NO-mediated mitochondrial effects
TSP-1/CD47 modulation Increased TSP-1 inhibits NO generation leading to vasoconstriction Increased tumor blood flow through anti–steal effect
Insulin and electrical stimulus Increased iNOS activity and NO Increased tumoral blood flow
Focused low-dose radiation None Increased tumor NO through eNOS up-regulation
Hypoxia-activated NO donors None Increased local NO concentration, modulation of tumor blood flow
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bioactivity can be exported selectively to hypoxic zones of the tumor,
dilating mature blood vessels and thereby facilitating O2 delivery.
Oxygen-Sparing Effects
Reoxygenation of tumors is linked to decreased oxygen consumption
[29]. NO and its oxidative product nitrite have been reported to in-
crease tumor oxygenation through inhibition of mitochondrial respira-
tion [30] by binding reversibly to cytochrome c oxidase in complex IV
[2]. Oxygen is thus redistributed [31] away from the electron transport
chain toward nonrespiratory oxygen-dependent targets like hypoxia-
inducible factor 1 (HIF-1). HIF-1, consisting of two subunits, HIF-1α
and HIF-1β, is the master regulator [32] of hypoxic stress. Under well-
oxygenated conditions, HIF-1α is in stasis—continuously synthesized
and degraded. At lowO2 concentrations, HIF-1α accumulates to hetero-
dimerize with HIF-1β and activates the expression of HIF-dependent
target genes such as VEGF, contributing to radioresistance [12]. By
contrast, NO-mediated tumor reoxygenation increases tumor radio-
sensitivity through resumption of HIF-1α degradation. These NO-
elicited events can also generate peroxynitrite that induces oxidative
stress and apoptosis [33] through different mechanisms, including
DNA cross-linking.
Radioprotection
The above notwithstanding, NO has also been described as a radio-
protectant. Liebmann et al. [34] demonstrated that pretreatment
with NO donors enhanced the survival of mice to whole body irradia-
tion and resulted in hemopoietic protection. Maxhimer et al. [35] re-
ported radioprotection of soft tissue and prevention of apoptosis in
irradiated muscle in vivo, presumably by increasing NO levels through
inhibition of CD-47 expression. There are a number of potential
mechanisms of healthy tissue radioprotection that are not necessarily
mutually exclusive with simultaneous tumor radiosensitization. These
include neutralization of radical nitrogen and oxygen species [36]. NO
is a free radical with an unpaired electron in the highest orbital, making
it highly reactive with other free radicals; therefore, by definition, NO
can act as an antioxidant through electron transfer to quench free radi-
cals. In addition, NO induces hypotension which results in decreased
blood flow to bone marrow through the vascular steal phenomenon.
Hence, paradoxically, the generation of hypoxia protects the cells in
the bone marrow from the effect of radiation. Finally, NO can also in-
hibit apoptosis depending on cell types and environmental conditions.
NO-Based Radiosensitization Strategies
Background
In 1957, Howard-Flanders [37] demonstrated radiosensitization of
hypoxic bacteria with NO gas. In the early 1990s, Mitchell et al. [38]
reported that an NO donor drug, diethylamine NO (DEA/NO), sen-
sitized hypoxic mammalian cells to irradiation as effectively as oxygen.
De Ridder et al. [13] confirmed these radiosensitizing effects with both
DEA/NO and spermine nonoate (SPER/NO), and the radiosensitivity
of experimental tumors after application of the NO donor SIN-1 was
demonstrated by Jordan et al. [39].
However, in contrast to these results, the NOS inhibitor nitro-L-
arginine was found to induce tumor radioresistance [39]. In the same
series of experiments, Jordan et al. [39] also demonstrated increased
tumor blood flow and in vivo radiosensitization after intraperitoneal
administration of isosorbide dinitrate. In contrast, using the NO donor
nitroprusside, Thews et al. [40] described decreased tumor perfusion in
rats bearing subcutaneous tumors, which correlated with a fall in mean
arterial blood pressure, suggesting the presence of a vascular steal
phenomenon. Similarly, Shan et al. [41] also reported that intravenous
injection of DEA/NO lowered mean arterial blood pressure and de-
creased tumor blood flow and oxygenation.
Clearly, these publications demonstrate that the effects of NO
donors on tumor blood flow and radiosensitization are not consistent
or predictable. In addition, the potential for dose-limiting hypotension
and vascular steal limits the clinical utility of NO donors as radio-
sensitizers of both currently approved NO donors (organic nitrates in-
cluding glyceryl trinitrate, isosorbide mononitrate, and dinitrate) and
the direct NO donors that include sodium nitroprusside and SIN-1.
A number of strategies to optimize the activity/toxicity profile of
NO manipulation have been studied. These include hypoxia-activated
NO donors, thrombospondin 1/CD-47 modulation, and indirect
activation of endogenous NOS (Table 2).
NO Manipulation Strategies for Radiosensitization
Hypoxia-Activated NO Donors.
a. S-nitroso-N -acetylpenicillamine and S-nitrosoglutathione:.
The nitrosonium ion (NO+) donors, S-nitroso-N -acetylpenicil-
lamine (SNAP) and S -nitrosoglutathione (GSNO), generate
NO bioreductively under hypoxic conditions, leading to in vitro
radiosensitization [42]. The mechanism is thought to include
delivery and release of NO through transnitrosylation steps.
However, the above NO+ donors have also been associated with
stabilization of HIF-1α [43], leading to the induction of HIF-1α
target genes, and radioresistant phenotypes, which would limit
their clinical utility.
b. RRx-001.
RRx-001, a nonexplosive pernitro compound possessing a novel
pharmacophore that originated in the defense industry, is a
small-molecule NO donor that is currently in a phase 1 clinical
trial. Preclinical studies demonstrated profound radiosensitiza-
tion in vivo at nontoxic doses that was accompanied by a signifi-
cant increase in tumor blood flow for up to 72 hours. At these
doses, normal GI epithelium was not sensitized to the effects of
radiation and may even have been protected [44].
Thrombospondin 1/CD-47 modulation. In contrast to directly
modulating NO levels, thrombospondin 1 (TSP-1), acting through
its receptor CD-47, antagonizes the effects of NO. TSP-1 expression
is frequently suppressed in tumors, preventing NO regulation and
Table 2. Direct and Indirect NO-Based Radiosensitization Strategies.
Direct Indirect
Hypoxia-activated NO donors NO response manipulation strategies
• SNAP and GSNO • Thrombospondin-1/CD-47 modulation
• RRx-001 (ABDNAZ)
Indirect activation of endogenous NOS
• Insulin and electrical stimulus
• Lipid A analog, ONO-4007
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thereby promoting NO proangiogenic effects. However, some tumors
induce an increase in systemic TSP-1 derived from nontumorigenic
stromal cells. The systemic increase in TSP-1 limits NO-driven re-
sponses in normal tissue and thereby induces an anti–steal effect by
increasing tumor perfusion to the detriment of healthy tissue circula-
tion [45]. Whereas local NO production drives tumor angiogenesis,
systemic NO-mediated vasodilation preferentially enhances normal
tissue perfusion at the expense of the tumor, similar to the steal effect.
Therapeutic concepts to modulate the TSP-1/CD47 interaction have
been described in the literature but have not advanced into formal
development [46].
Indirect activation of endogenous NOS.
a. Insulin and electrical stimulus.
Jordan et al. [15] reported that insulin infusion and electrical
stimulation of the host tissue radiosensitized experimental tu-
mors in vivo through increased NO [13] production from the
endothelial isoform of NOS (eNOS). The authors speculate that
both treatments resulted in tumor reoxygenation from increased
blood flow and/or reduced oxygen consumption due to de-
creased mitochondrial respiration. The increase in tumor oxy-
genation, and the radiosensitizing effect, was completely
abolished in eNOS knockout mice.
b. Lipid A analog, ONO-4007.
ONO-4007 is a synthetic analog of the lipid A moiety of gram-
negative bacterial lipopolysaccharide. Preclinical data have dem-
onstrated that the compound radiosensitizes with considerably
less toxicity than lipopolysaccharide in animal models of malig-
nancy [13]. The mechanism of action is thought to involve ac-
tivation of the interferon-γ pathway and induction of NOS [47].
In a phase 1 trial, an MTD dose was reached, and although no
objective responses were seen, disease stabilization was observed
in five patients for the duration of the study (18 weeks) [48]. No
information on a phase 2 trial is available.
Discussion and Conclusions
Like the word “NO,” the use of NO, even as an electrically neutral
molecule, in radiotherapy is highly charged. The challenge of how
to reconcile the therapeutic potential of NO with its seeming duality
is perhaps best addressed by considering that the effects of oxygen may
bemediated through NO [12]. More thanmerely a conduit for oxygen,
however, NO is a cooperative partner that actively facilitates the de-
livery and use of oxygen and regulates the toxicity of oxygen reactive
intermediaries in both normal and tumor tissues.
From this perspective, the relationship between oxygen and NO
recapitulates elements of a feedback control that can be manipulated
with pathophysiological and therapeutic implications. As the inter-
mediary between the host macroenvironment and the tumor micro-
environment, NO is the effector of this feedback interaction. This
function requires a careful balancing act with the radiobiological
outcome critically dependent on the concentration and location of
both species.
The inconsistent results of tumor reoxygenation and NO manipu-
lation as separate radiosensitization strategies may be related to the fail-
ure to explore integrated interventions that exploit NO and oxygen
together in the context of the tumor microenvironment. This ren-
ders NO manipulation an ideal candidate for a personalized systems
biology type of approach tailored both to the NO/O2 axis of specific
patients and biologic features of tumors.
However, more nonclinical basic research under carefully defined
and controlled conditions is required to fully understand and delineate
the role of NO in the context of radiosensitization and to demonstrate
that manipulation of NO may be beneficial for improving radiation
response. The NO-mediated radiosensitization approaches described
in this review are either well established and clinically explored or
groundbreaking but still at a very early, nonclinical stage with the
exception of RRx-001, a novel hypoxia-activated NO donor, cur-
rently in phase 1 trials. This promising approach has the potential
of exploiting NO for radiosensitization while avoiding systemic NO-
based effects.
Currently, the understanding of the clinical role and utility of
NO in the context of radiosensitization is poorly understood and the
effects are contradictory. Whether NO directly or indirectly functions
as a radiosensitizer may ultimately be contextual to the tumor micro-
environment and the specific architecture of the vasculature, particu-
larly the presence or absence of smooth muscle coverage that allow
the vessel to respond to a vasoactive stimulus through endogenous or
external NO delivery.
As effective radiosensitization strategies represent an unmet need in
the treatment of cancer, the development of new agents that specifically
and selectively deliver NO to the tumor enabling local exposure affect-
ing vasodilation, mitochondrial respiration, and red blood cell rheology,
but without adverse systemic effects, represent an exciting future for
NO-driven radiosensitizers.
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